US20080274097A1

US20080274097A1 - Booster for therapy of diseases with ultrasound and pharmaceutical liquid composition containing the same

Info

Publication number: US20080274097A1
Application number: US12/172,686
Authority: US
Inventors: Katsuro Tachibana; Shunro Tachibana
Original assignee: Individual
Current assignee: Individual
Priority date: 1991-03-22
Filing date: 2008-07-14
Publication date: 2008-11-06
Also published as: US5315998A; CA2063529A1; EP0732106A3; EP0504881A2; DE69215722T2; US20030191446A1; US6585678B1; ATE146073T1; EP0504881A3; EP0504881B1; DE69215722T3; USRE36939E; EP0732106A2; DE69215722D1; EP0504881B2

Abstract

A booster comprising a plurality of microbubbles of a gas in a liquid, e.g. about 4×10⁷cells/ml of microbubbles of a gas having a diameter of 0.1 to 100 μm in a 3 to 5% human serum albumin solution, and a pharmaceutical liquid composition comprising the booster as set forth above and a medicament, which are useful for the therapy of various diseases together with exposure of ultrasonic, where the therapeutic effects of the medicament is enhanced by the application of ultrasound in the presence of the booster.

Description

RELATED APPLICATIONS

This application is a continuation of application Ser. No. 10/400,337, filed Mar. 26, 2003, which is a continuation of application Ser. No. 09/375,339, filed Aug. 16, 1999, now U.S. Pat. No. 6,585,678, which is a divisional of application Ser. No. 08/652,690, filed May 30, 1996, now U.S. Pat. No. RE36,939, which is a reissue of U.S. Pat. No. 5,315,998, filed Mar. 20, 1992. This application also claims priority under §119 to Japanese Application No. 3-058970, filed Mar. 22, 1991. Each of the above-referenced related applications is incorporated herein by reference in its entirety

FIELD OF THE INVENTION

This invention relates to a booster useful for enhancing the effects of ultrasound in the therapy of various diseases and a pharmaceutical liquid composition containing the booster and a medicament which shows enhanced diffusion and penetration of the medicament into the body by applying ultrasound. More particularly, it relates to a booster useful for therapy of various disease by applying ultrasound which comprises a plurality of microbubbles of a gas in a liquid, a pharmaceutical liquid composition comprising a plurality of microbubbles of a gas and a medicament in a liquid, and the use thereof in the therapy of various diseases while applying ultrasound.

BACKGROUND

It is known that various diseases are remedied by the aid of ultrasonic vibration. For example, it is described in Japanese Patent First Publication (Kokai) No. 115591/1977, etc. that percutaneous absorption of a medicament is enhanced by applying an ultrasonic vibration. Japanese Patent First Publication (Kokai) No. 180275/1990 discloses a drug-injecting device which is effective on the diffusion and penetration of the drug by applying an ultrasonic vibration in the step of injecting a drug into a human body via a catheter or a drug-injecting tube. U.S. Pat. Nos. 4,953,565 and 5,007,438 also disclose the technique of percutaneous absorption of medicaments by the aid of ultrasonic vibration. It is also reported that a tumor can be remedied by concentratedly applying ultrasound from outside the body.
In order to enhance the therapeutic effects with ultrasound, it is required to apply a high energy ultrasonic vibration. However, ultrasonic vibration at an energy that is too high causes disadvantageously bums or unnecessary heat at the portion other than the desired portion. On the other hand, when the energy of an ultrasonic vibration is lowered for eliminating such disadvantages, there is a problem of less effect of the ultrasound at the desired portion.

SUMMARY OF THE INVENTION

The present inventors have intensively studied enhancing the effects of ultrasound at a lower energy of an ultrasonic vibration and have found that a booster comprising a plurality of microbubbles of a gas in a liquid is useful for the desired enhancement of the effects of ultrasound.
An object of the invention is to provide a booster useful for enhancing the effects of ultrasound which comprises a plurality of microbubbles of a gas in a liquid. Another object of the invention is to provide a pharmaceutical liquid composition containing the booster and a medicament which is useful for the therapy of various diseases together with the application of ultrasound. A further object of the invention is to provide a method for enhancing the effects by the application of ultrasound in the therapy of various diseases which comprises injecting the booster or the pharmaceutical liquid composition as set forth above into the portion to be remedied while applying ultrasound thereto. These and other objects and advantages of the invention will be apparent to those skilled in the art from the following description.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a schematic view of one of the microbubbles contained in the booster of the invention.

FIG. 2 shows a schematic sectional view of one embodiment of a drug administration device used for injecting, pouring, applying or circulating the booster or the pharmaceutical liquid composition of the invention.

FIG. 3 shows a schematic sectional view of one embodiment of a drug administration device used for transdermal administration of the booster or the pharmaceutical liquid composition of the invention.

FIG. 4 and FIG. 5 show graphs showing fibrinolysis by application of ultrasound with or without the booster of the invention.

DETAILED DESCRIPTION OF THE INVENTION

The booster of the invention comprises a liquid containing a plurality of microbubbles of a gas having a diameter of 0.1 to 100 μm. The microbubbles are formed by entrapping microspheres of a gas into a liquid. The booster contains, for example, about 4×10⁷of the microbubbles per one milliliter of a liquid. The microbubbles are made of various gases such as air, oxygen gas, carbon dioxide gas, inert gases (e.g. xenon, krypton, argon, neon, helium, etc.), preferably air and oxygen gas. The liquid includes any liquid which can form microbubbles, for example, human serum albumin (e.g. 3 to 5% human serum albumin), a physiological saline solution, a 5% aqueous glucose solution, an aqueous indocyanine green solution, autoblood, an aqueous solution of maglumine diatriazoate (=renografin), and any other X-ray contrast medium.
The booster can be prepared by a known method, for example, by agitating the liquid as mentioned above while blowing a gas as mentioned above into the liquid, or alternatively exposing the liquid to ultrasound with a sonicator under a gaseous atmosphere, whereby a vibration is applied to the liquid to form microbubbles of the gas.
The pharmaceutical liquid composition of the invention comprises a plurality of microbubbles of a gas and a medicament in a liquid. The microbubbles of a gas and liquid are the same as mentioned above. The medicament includes any known medicaments effective for the desired therapy which can be absorbed percutaneously, for example, anti-thrombosis agents (e.g. urokinase, tissue plasminogen activator, etc.), hormones (e.g. insulin, etc.), theophylline, lidocaine, antibiotics, antineoplastic agents which are sensitive to ultrasound (e.g. doxorubicin (=adriamycin), cytarabine (=Ara.C), etc.), and the like. The medicament can be contained in a therapeutically effective amount as usually used. The pharmaceutical liquid composition can be prepared by mixing a medicament with a booster comprising a plurality of microbubbles of a gas in a liquid. The mixing ratio may vary depending on the desired amount and kind of the medicament and the kind of the liquid, but is usually in a range of 1:100 to 100:1 by weight (a medicament/a booster).
According to the invention, the therapeutic effect of ultrasound is boosted by the presence of a booster of the invention. Particularly, when a pharmaceutical liquid composition containing the booster and a medicament is poured or injected into a body in parenteral routes, such as intravenously, percutaneously or intramuscularly, while applying thereto an ultrasonic vibration, the therapeutic effects of the medicament is significantly enhanced. When an ultrasound from an ultrasonic element is applied to the liquid containing the booster and medicament, cavitation occurs in the liquid composition, and the medicament is diffused and penetrated into the desired portion of the biobody by the aid of vibration induced by the cavitation. The cavitation occurs when the level of vibration energy exceeds a certain threshold value. When the ultrasound is applied to the liquid composition of the invention, the threshold value of the vibration energy is reduced due to the presence of a plurality of microbubbles of a gas. That is, the microbubbles of a gas act as nucleus of cavitation and thereby the cavitation occurs more easily. Therefore, according to the invention, the desired ultrasonic energy necessary for the desired diffusion and penetration of a medicament is reduced.
The desired ultrasound is applied by conventional ultrasonic devices which can supply an ultrasonic signal of 20 KHz to several MHz.
With reference to the accompanying drawings, the invention is illustrated in more detail.
FIG. 1 shows a schematic view of one of the plurality of microbubbles of a gas contained in the booster of the invention, wherein the microbubble of a gas has a diameter of 0.1 to 100 μm and is composed of a shell of human serum albumin 1 and gas 2 entrapped within the microbubble. The microbubbles are contained in a liquid 3 such as 5% human serum albumin solution in an amount of, for example, above 4×10⁷cells/ml.
The booster is mixed with a medicament to give a pharmaceutical liquid composition. The pharmaceutical liquid composition is directly administered to the diseased part with an appropriate device, for example, with a drug administration device 4 as shown in FIG. 2. The drug administration device 4 comprises a base tube 5 to which the pharmaceutical liquid composition is supplied, and an end tube 6 which is to be inserted into the tissue of the biobody and through which the pharmaceutical liquid composition is poured or injected into the disease part. The end tube 6 is provided with an ultrasonic element 7 (e.g. a cylindrical ceramic oscillator, etc.). The ultrasonic element 7 is supplied by an ultrasonic signal of 20 KHz to several MHz from an ultrasonic oscillation circuit 8 via a conductor 9 a, connectors 10 a and 10 b provided on the side of the base tube 5, a part of the base tube 5 and a conductor 9 b provided within the end tube 6.
The application or injection of a medicament is carried out in the form of a pharmaceutical liquid composition which is prepared by previously mixing the medicament with the booster comprising a plurality of microbubbles of a gas in a liquid, wherein the medicament and the booster are mixed in a ration of 1:100 to 100:1 by weight. The pharmaceutical liquid composition is poured into the base tube 5 from the supply opening 11 provided on the tip of the base tube 5, passes through a flow path 12 within the base tube 5 and a flow path 13 within the end tube 6 and is then administered to the diseased part or the portion close thereto of the patient via a pouring opening 14 provided at the bottom of the end tube 6.
When the pharmaceutical liquid composition is administered into the diseased part or the portion close thereto through the pouring opening 14, an ultrasonic energy generated from an ultrasonic element 7 is applied to the liquid composition, by which cavitation occurs due to the ultrasonic energy. Microbubbles are formed at the occurrence of cavitation and when the microbubbles are decomposed, energy is generated, by which diffusion and penetration of the medicament is promoted. Since the pharmaceutical liquid composition contains a plurality of microbubbles of a gas, the microbubbles act as a nucleus for the cavitation by which the cavitation occurs more easily, in other words, the threshold value of occurrence of cavitation lowers. Accordingly, it is possible to generate the cavitation with less energy than the case of using no booster.
When an ultrasonic vibration is applied to a liquid, if the liquid contains any material being able to become a nucleus, the cavitation occurs generally at a lower threshold value of energy, but it has been found that the cavitation occurs most easily where the liquid contains microbubbles of a gas having a diameter of 0.1 to 100 μm.
The drug administration device 4 as shown in FIG. 2 can be used, for example, for administering a pharmaceutical liquid composition into a blood vessel. For instance, in the treatment of coronary thrombosis, a pharmaceutical liquid composition comprising a booster of the invention and a urokinase is injected into the part of thrombosis or the close portion thereof with the drug administration device 4 where the tip of the end tube 6 is inserted into the portion close to the thrombosis with applying ultrasound, by which the thrombolytic effects of the medicament are significantly increased and further the blood flow is recovered within a shorter period of time in comparison with the administration of the medicament without the booster. The drug administration device 4 may also be used for the removing hematoma in bleeding of brain. For example, a pharmaceutical liquid composition comprising a booster of the invention and a thrombolytic agent (e.g. urokinase) is administered to the portion of hematoma with the drug administration device 4 with applying ultrasound like the above, by which the hematoma is easily lysed.
In another embodiment of the invention, the pharmaceutical liquid composition can be administered transdermally with a drug administration device 15 as shown in FIG. 3.
In the drug administration device 15 suitable for transdermal administration of a medicament, a layer of a medicament 17 is provided below an ultrasonic element 16 (e.g. a disc shaped ceramic oscillator, etc.), under which an adhesive layer 18 having a medicament permeability is laminated, the whole of which is covered with a plastic cover 19. The ultrasonic element 16 is supplied by ultrasonic signal from an ultrasonic oscillation circuit provided outside via a connector 20, as shown in the drug administration device 4 in FIG. 2.
In the device 15 of FIG. 3, a pharmaceutical liquid composition comprising a mixture of a booster and a medicament is contained in the layer of a medicament 17. When this device 15 is used, it is adhered onto the skin with facing the adhesive layer 18 to the skin, and then an ultrasonic signal is supplied to the ultrasonic element 16, by which an ultrasonic vibration from the ultrasonic element 16 is given to both of the medicament layer 17 and the skin and thereby the medicament contained in the medicament layer 17 is passed through the skin and is penetrated into the tissue to be treated. In this embodiment, since microbubbles of a gas are contained in the medicament layer 17, cavitation occurs easily within the medicament layer 17 by application of ultrasound, and hence even when lower energy of the ultrasonic vibration is supplied from the ultrasonic element 16, the diffusion and penetration of the medicament can effectively be done to result in rapid absorption of the medicament.
The booster of the invention may also be used alone without mixing with a medicament in the therapy with ultrasound. For example, in the therapy of tumors by heating the diseased part of the tissue with ultrasound, that is, by concentratedly applying an ultrasonic vibration outside the biobody, a booster comprising a plurality of microbubbles of a gas in a liquid of the invention is previously injected into the blood vessel or to the portion close to the diseased part before application of ultrasound, by which the effect of heating with ultrasound is enhanced and thereby the therapeutic effects are significantly improved. In this embodiment, cavitation occurs also by the ultrasonic vibration more easily because of using a liquid containing microbubbles of a gas, and hence, even by less energy of the ultrasonic vibration supplied from the ultrasonic element, the ultrasonic energy sufficient to the therapy is obtained and thereby the undesirable burns and unnecessary heating at other portions can L be avoided.
In the treatment of tumors, it is, of course, more effective to use it together with a chemotherapeutic agent suitable for the treatment of the tumors, by which the effects of the chemotherapeutic agent are more enhanced, where the diffusion and penetration of the medicament are improved owing to the booster.
The substance such as human serum albumin in the booster of the invention is easily metabolized within the biobody and excreted outside the biobody, and hence, it is not harmful to human body. Besides, the amount of gas trapped within the microbubbles is extremely small and is easily dissolved in the blood fluid. Accordingly, the booster of the invention has no problem in the safety thereof.
The preparation of the booster and pharmaceutical liquid composition of the invention and effects thereof are illustrated by the following Examples and Experiment, but it should not be construed to be limited thereto.

EXAMPLE 1

Preparation of a Booster:

A 5% human serum albumin (8 ml) in a 10 ml-volume syringe is exposed to ultrasound with a sonicator (frequency, 20 KHz) by which vibration is given to the human serum albumin and a plurality of microbubbles of air are formed in the human serum albumin to give a booster comprising a human serum albumin containing a plurality of microbubbles of air.

EXAMPLE 2

Preparation of a Pharmaceutical Liquid Composition:

The 5% human serum albumin containing a plurality of microbubbles of air prepared in Example 1 is mixed with urokinase (concentration 1200 IU/ml) to give the desired pharmaceutical liquid composition.

Experiment

1. Forming Artificial Thrombosis

An artificial thrombosis was formed by Chandler's method. Blood (1 ml) that was collected from healthy humans (two persons) was entered into a flexible tube (inside diameter 3 mm, length 265 mm) and thereto was added calcium chloride, and then the tube was made a loop like shape, which was rotated at 12 rpm for 20 minutes to give an artificial thrombosis model.

2. Ultrasonic Catheter

A ceramic ultrasonic element (width 2 mm, length 5 mm, thickness 1 mm) was inserted into the tip of a catheter (diameter 2 mm), and an oscillating element was connected to an oscillator provided outside with a fine connector passed through the catheter. A fine tube for pouring a test solution was provided at an opening opposite to the opening of the catheter end.

3. Test Method

The artificial thrombosis prepared above was added to a test tube together with blood, and the ultrasonic catheter was inserted into the test tube so that the end of the catheter was set close to the portion of the artificial thrombosis (at a distance of about 5 mm), and to the test tube a mixture of urokinase and a booster prepared in Example 1 was added at a rate of 1 ml per minute, wherein urokinase (concentration 1200 IU/ml) and the booster were mixed immediately before pouring at a mixing ration of 1:1 by weight. The mixture was refluxed while keeping the volume of the test solution at a constant level by removing excess volume of the solution by suction. The ultrasound (170 KHz) was exposed to the mixture by a pulse method (exposed for 2 seconds and stopped for 4 seconds) for 2 minutes (total exposing time 40 seconds). After the exposure, the ultrasonic catheter was removed from the test tube, and the mixture was incubated at 37 degrees C. for 5 to 120 minutes, washed with a physiological saline solution several times and dried overnight. Thereafter, the dried mixture was weighed. As a control, the above was repeated by using only a physiological saline solution.

4. Test Results

The rate of fibrinolysis was calculated by the following equation:
$Fibrinolysis rate (%) = \frac{[\begin{matrix} Weight of \\ thrombosis in control \end{matrix}] - [\begin{matrix} Weight of \\ thrombosis treated \end{matrix}]}{Weight of thrombosis in control} \times 100$
The results are shown in the accompanying FIGS. 4 and 5 wherein there are shown in average of twice tests.
FIG. 4 shows the results in the thrombosis prepared by using blood collected from one person, wherein the symbol —□— is the data obtained in the addition of urokinase alone without exposure of ultrasound, —♦— is the data obtained in the addition of urokinase alone with exposure of ultrasound, and —▪— is the data obtained in the addition of a mixture of urokinase and the booster with exposure of ultrasound.
As shown in FIG. 4, the time for achieving 20% fibrinolysis was 45 minutes by urokinase alone without exposure of ultrasound, 30 minutes by a combination of urokinase and exposure of ultrasound, and only 10 minutes by a combination of a mixture of urokinase and a booster and exposure of ultrasound. The fibrinolytic effects of urokinase (both the rate of fibrinolysis and the fibrinolytic time) were significantly enhanced by using a booster with application of ultrasound.
FIG. 5 shows the results in the thrombosis prepared by using blood collected from another person and with reduced energy of ultrasound by 15%, wherein the symbols are the same as in FIG. 4. As shown in FIG. 5, the fibrinolytic effects were significantly enhanced by using a mixture of urokinase and the booster. That is, in case of using urokinase alone with exposure of ultrasound, the 50% fibrinolysis was achieved by the treatment for 60 minutes, but in case of using a mixture of urokinase and the booster with exposure of ultrasound, it reduced to one fourth, i.e. it was achieved by the treatment only for 15 minutes.

Claims

1. A method of enhancing the effects of ultrasound energy at a treatment site, comprising:

advancing a distal end portion of an elongate tube toward the treatment site;

delivering a pharmaceutical liquid composition through a lumen of said elongate tube; and

emitting ultrasound energy at a frequency between about 20 KHz to about several MHz into said pharmaceutical liquid composition to promote diffusion of said medicament at the treatment site.

2. The method of claim 1 wherein said pharmaceutical liquid composition comprises a medicament.

3. The method of claim 2 wherein said medicament comprises a hormone.

4. The method of claim 2 wherein said medicament comprises an antibiotic.

5. The method of claim 2 wherein said medicament comprises a chemotherapeutic agent.

6. The method of claim 2 wherein said medicament comprises an antineoplastic agent.

7. The method of claim 6 wherein said antineoplastic agent is doxorubicin.

8. The method of claim 6 wherein said antineoplastic agent is cytarabine.

9. The method of claim 2 wherein said medicament comprises an antithrombotic agent.

10. The method of claim 2 wherein said medicament comprises a thrombolytic agent.

11. The method of claim 10 wherein said thrombolytic agent comprises urokinase.

12. The method of claim 10 wherein said thrombolytic agent comprises tissue plasminogen activator.

13. The method of claim 1, wherein the ultrasound energy is emitted from an ultrasonic element disposed along said distal end portion of said elongate tube.

14. A method of enhancing the effects of ultrasound energy at a treatment site, comprising:

advancing a distal end portion of an elongate tube toward the treatment site;

delivering a pharmaceutical liquid composition through a lumen of said elongate tube;

emitting ultrasound energy at a frequency between about 20 KHz to about several MHz into said pharmaceutical liquid composition to promote diffusion of said medicament at the treatment site; and

generating cavitation at the treatment site.

15. The method of claim 14 wherein said pharmaceutical liquid composition comprises a medicament.

16. The method of claim 15 wherein said medicament comprises a thrombolytic agent.

17. The method of claim 16 wherein said thrombolytic agent comprises urokinase.

18. The method of claim 16 wherein said thrombolytic agent comprises tissue plasminogen activator.